Business
Announcement on Acceptance of Clinical Trial Application for Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli)
Announcement on Acceptance of Clinical Trial Application for Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli)
About this update from Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. Class A
Announcement on Acceptance of Clinical Trial Application for Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli) The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment